Abstract: A method for controlling a laundry washing machine. The method includes: performing a tub loading process comprising operating supply valve(s) to provide a first volume of water through a detergent supply system and into a tub to fill the tub with wash liquid; performing a washing process comprising rotating a drum to agitate laundry in in the presence of the wash liquid; performing a static rinsing process comprising operating a pump to remove any free volume of wash liquid from the tub without rotating the drum; and performing one or more rinsing processes comprising: operating the supply valve(s) to provide a volume of clean rinse water to the tub, operating the pump to remove the rinse water from the drum, and operating the motor to spin the drum at high speed to extract rinse water from the laundry, while continuing to operate the pump.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor of Formula (I).

Abstract: The present invention discloses a technique of preparation of composite nanodots, and their use in the field of photoacoustic imaging, wherein, the main components of the composition are carbon nanodots, and supporting component is methylene blue, and the composition has favourable biocompatibility characteristics with the average grain size of 150-300 nanometers, and the average zeta potential of ?15 to 5 millivolts. The above said techniques for preparation of composite nanodots are safe, quick and simple, low cost, and easy to perform for industrialized production. Composite carbon nanodots have good biocompatibility and safety, high photoacoustic imaging sensitivity, and it is promising in gaining wider use in the fields of biomedical imaging, targeting diagnosis and therapy, drug screening and optimization, and in vivo labelling and tracing, and has potential value in personalized medicine.

Abstract: The present invention discloses a preparation technique of composite nanodots based on carbon nanodots, and their use in the field of fluorescent imaging, wherein, the main components of the composition are carbon nanodots, which are material with superior biocompatibility characteristics, and supporting component is methylene blue, and particle diameter range is 100-500 nanometers, and the zeta potential is ?35 to 10 millivolts. The above said techniques for preparation of composite nanodots are safe, quick and simple, low cost, and easy to perform for industrialized production. Composite carbon nanodots have good biocompatibility and safety, high fluorescence imaging sensitivity, and they are promising in gaining wider use in the fields of biomedical imaging, targeting diagnosis and therapy, drug screening and optimization, and in vivo labelling and tracing, and have potential value in personalized medicine.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: A gateway receives a link state packet (LSP) that includes a network identifier of a Layer 2 virtual network and a multicast address and that is sent by each routing bridge (RB) that is on the Transparent Interconnection of Lots of Links (TRILL) network; separately performs calculation on the network identifier and the multicast address that are in each LSP, to obtain a calculation result corresponding to each combination of the network identifier and the multicast address; if the gateway determines that information preconfigured on the gateway matches a calculation result corresponding to a combination of the network identifier and the multicast address, sends a notification message including the network identifier and the multicast address that are in the matched combination to each RB; receives from at least one RB, a multicast packet corresponding to the multicast address in the matched combination, and forwards the multicast packet.

Abstract: A polybutylacrylate-based nanocomposite photoacoustic imaging agent includes a biomedical material such as polybutylacrylate used as a main component and methylene blue or indocyanine green used as an entrapped component with particle diameters of 525.1 nm and 272.0 nm and electric potentials of ?4.52 mV and ?5.98 mV respectively. The preparation method of the polybutylacrylate-based nanocomposite photoacoustic imaging agent with the features of moderate eco-friendliness, low power consumption, and free of three industrial wastes, radiation, and noise pollution may be used for industrial production.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I or II, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor of Formula (I).

Abstract: A gateway receives a link state packet (LSP) that includes a network identifier of a Layer 2 virtual network and a multicast address and that is sent by each routing bridge (RB) that is on the Transparent Interconnection of Lots of Links (TRILL) network; separately performs calculation on the network identifier and the multicast address that are in each LSP, to obtain a calculation result corresponding to each combination of the network identifier and the multicast address; if the gateway determines that information preconfigured on the gateway matches a calculation result corresponding to a combination of the network identifier and the multicast address, sends a notification message including the network identifier and the multicast address that are in the matched combination to each RB; receives from at least one RB, a multicast packet corresponding to the multicast address in the matched combination, and forwards the multicast packet.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I or II, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: The present invention provides kinase inhibitors of Formula I.

Abstract: The present invention provides kinase inhibitors of Formula I.